Home > Boards > US Listed > Biotechs > Heron Therapeutics Inc. (HRTX)

I always felt Sustol was simply the validation

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
sparkyone Member Profile
 
Followed By 0
Posts 630
Boards Moderated 0
Alias Born 05/06/08
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/23/2019 8:40:33 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/21/2019 9:16:32 AM
Heron Therapeutics Announces Publication of Results from Phase 3 EPOCH 1 Study of HTX-011 in Patients Undergoing Bunionectomy PR Newswire (US) - 5/21/2019 9:13:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/16/2019 8:45:48 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/14/2019 8:36:20 AM
Heron Therapeutics Presents New Results from Real-world Study Showing 95% of Postoperative Patients Remain Opioid-Free when H... PR Newswire (US) - 5/14/2019 8:30:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/9/2019 8:45:52 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/9/2019 8:40:44 AM
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2019 and Highlights Recent Corporate Prog... PR Newswire (US) - 5/9/2019 8:30:00 AM
Heron Therapeutics to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference PR Newswire (US) - 5/8/2019 4:05:00 PM
Heron Therapeutics Partners with the National Academy of Medicine to Counter the Opioid Epidemic in the United States PR Newswire (US) - 5/7/2019 4:05:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/1/2019 8:08:05 AM
Heron Therapeutics Receives Complete Response Letter For HTX-011 For The Management Of Postoperative Pain PR Newswire (US) - 5/1/2019 8:00:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/26/2019 4:58:18 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/26/2019 4:54:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/1/2019 8:37:13 AM
Heron Announces European Medicines Agency Validation of Marketing Authorisation Application for HTX-011 for Postoperative Pai... PR Newswire (US) - 4/1/2019 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/11/2019 8:40:24 AM
77% of Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in New Multi-center Posto... PR Newswire (US) - 3/11/2019 8:30:00 AM
Heron Therapeutics to Present at the 39th Annual Cowen Healthcare Conference PR Newswire (US) - 3/4/2019 4:05:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/26/2019 4:13:24 PM
Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTIĀ® Label for IV Push PR Newswire (US) - 2/26/2019 4:05:00 PM
Annual Report (10-k) Edgar (US Regulatory) - 2/22/2019 8:50:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/22/2019 8:42:05 AM
Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2018 and Recent Corporate P... PR Newswire (US) - 2/22/2019 8:30:00 AM
sparkyone   Friday, 05/13/16 08:21:16 AM
Re: Jumpinjackas post# 5849
Post # of 5890 
I always felt Sustol was simply the validation of the delivery system. Any approval means they can move forward with dozens of indications. Pain management is big!
This whole thing is about nano technology applied to existing approved meds. Very interesting and an easy path to take. Tang is brilliant.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist